Cancer genomics has produced extensive information on cancer-associated genes but the 9 number and specificity of cancer driver mutations remains a matter of debate. We constructed 10 a bipartite network in which 7665 tumors from 30 cancer types are connected via shared 11 mutations in 198 previously identified cancer-associated genes. We show that 27% of the 12 tumors can be assigned to statistically supported modules, most of which encompass 1-2 13 cancer types. The rest of the tumors belong to a diffuse network component suggesting lower 14 gene-specificity of driver mutations. Linear regression of the mutational loads in cancer-15 associated genes was used to estimate the number of drivers required for the onset of 16 different cancers. The mean number of drivers is ∼2, with a range of 1 to 5. Cancers that are 17 associated to modules had more drivers than those from the diffuse network component, 18
Introduction 20
Cancer develops as a result of accumulation of somatic mutations that impair cell division 21 checkpoints, resulting in abnormal cell proliferation and eventually tumorigenesis 1, 2 . Such 22 mutations are called "drivers" because they are thought to drive their carrier towards a 23 cancerous state. Characterization of driver mutations is central to understanding the early 24 steps of tumor progression 3, 4 . During the last decade, comparative analyses of large collections 25 of cancer genomes have led to the identification of overlapping sets of genes that are typically 26 associated to cancer, i.e. harbor a significant excess of mutations in tumors and show 27 signatures of positive selection 5-10 . The continued identification of cancer-associated genes 28 provides insights into the processes and pathways involved in tumorigenesis, as well as 29 possible therapy targets [11] [12] [13] [14] [15] [16] . Like any other gene in the genome, cancer-associated genes are 30 expected to accumulate passenger mutations that do not contribute to or even hinder cancer 31 progression 17 . Therefore, although cancer-associated genes harbor numerous driver 32 mutations, only a fraction of the mutations found in these genes are actual drivers 10 . 33
Distinguishing driver mutations from passenger ones poses a formidable challenge for cancer 34 genomics. The number of driver mutations required for the onset of cancer is a fundamental 35 question that remains a matter of debate 3, 9, [18] [19] [20] . Classical approaches to this problem use age 36 Fig. S1 ). A closer inspection of inter-module mutations highlights oncogenes BRAF and IDH1 as 120 major sources of inter-module driver mutations in melanomas and acute myeloid leukemia, 121 respectively, with missense mutations representing 96% of the coding mutations in both genes 122 compared to the 84% baseline. Similarly, tumor suppressor genes STAG2, KDM6A, PIK3R1, 123 MAP3K1, and CDH1, with 50-60% of truncating mutations (16% baseline), constitute probable 124 inter-module drivers, with MAP3K1 and CDH1 being more relevant in breast cancer. 125
Specificity modules for cancer types and cancer-associated genes 126
As shown in Table 1 , the composition of the gene-sample specificity modules strongly 127 correlates with the histological classification of tumors. Most modules include tumors from 128 one or two cancer types, together with genes for which mutation frequencies are significantly 129 higher in cancers of those types (Fig. 2) . The mutual specificity analysis recovers some well-130 established features of cancer mutational landscapes, such as the association between thyroid 131 cancer and BRAF, or between colorectal cancer and APC, KRAS, TP53, and SMAD4. The 132 colorectal cancer module includes two additional genes that are mutated in a smaller fraction 133 of samples, namely, ubiquitin ligase FBXW7 and transcription factor TCF7L2. Most samples 134 from pancreatic adenocarcinoma cluster in the same module as colorectal cancer, in 135 agreement with a significant excess of mutations in KRAS, TP53 and SMAD4 in both tumor 136 types. Acute myeloid leukemia constitutes a single module, with the genes DNMT3A, FLT3 and 137 NPM1 mutated in >30% samples, and CEBPA, IDH2, RUNX1 and WT1 mutated at lower 138 frequencies. Testicular germ cell cancer, head and neck squamous cell carcinoma, and 139 urothelial bladder carcinoma also form separate modules which, however, comprise a smaller 140 fraction of the samples from each cancer type. The sets of associated genes include KIT in 141 testicular cancer; NOTCH1, CASP8, HLA-A and HRAS in head and neck cancer; and FGFR3, 142 KDM6A and STAG2 in bladder cancer. Clear cell kidney carcinoma clusters with genes VHL, kidney carcinoma are also assigned to that module, mostly because of mutations in SETD2 and 145
BAP1. 146
Notably, some cancer types are distributed among more than one module. Thus, glioblastoma 147 is represented in two modules, one characterized by mutations in EGFR and PTEN, and the 148 other by mutations in IDH1, ATRX and TP53. Such subdivision is consistent with previous 149 reports, which relate the second group with the glioblastoma-CpG island methylator 150 phenotype [33] [34] [35] . The same module also includes most samples from lower grade glioma and 151 some representatives from sarcoma (though the latter typically lack mutations in IDH1). 152
Similarly, melanoma is divided into tumors with mutated BRAF on a low mutational 153 background, which cluster with thyroid cancer, and samples with mutations in a larger set of 154 genes (including NRAS, KDR, ILR7, PTPRB), which constitute a separate module. Finally, breast 155 cancer splits between a breast cancer-only module characterized by mutations in GATA3 and 156 TBX3, and a larger module that includes uterine (endometrial and carcinosarcoma) and 157 prostate cancers, with PIK3CA as the signature gene. In terms of histological types, the PIK3CA 158 module is significantly enriched in lobular breast tumors (46% compared to 13% in the 159 GATA3/TBX3 module and 17% in the entire dataset, Chi-squared test p < 10 -6 ). In terms of the 160 molecular subtypes, both modules include breast tumors that mostly belong to the luminal 161 subtype (estrogen receptor-positive), whereas most of the basal-like breast tumors are not 162 assigned to any significant module (Chi-squared test p < 10 -10 ). 163
Among all the modules, the one that combines breast, uterine and prostate cancers stands out 164 for its size and diversity. This module contains the largest number of genes, with many of those 165 mutated in less than 30% of the samples. Moreover, two of its constituent histologies, breast 166 cancer and uterine carcinosarcoma, are split between this and other modules. To further 167 dissect the specificity of the mutations affecting these cancer types, we reanalyzed the 168 subnetwork composed by all cancer genes and samples from breast, prostate and uterine 9 dominated by each of the 4 cancer types. The list of module-specific genes is consistent with 171 the findings of the global analysis. Notably, the re-analysis places most breast cancer samples 172 in a single module with genes CDH1, PIK3CA, GATA3 and TBX3, whereas uterine 173 carcinosarcoma clusters with genes FBXW7, PPP2RIA and TP53 (the samples without 174 mutations in PPP2RIA were formerly assigned to the colorectal cancer module). Specific 175 modules for prostate and endometrial cancer are also clearly delineated, the former with SPOP 176 and FOXA1, the latter with ARID1A, CTNNB1, PI3KR1 and PTEN, among other genes. 177
Two major modes of driver accumulation 178
The statistically significant modules of mutual tumor-gene specificity include 27% of the 179 tumors in the TGCA. There are at least two alternative explanations for why 73% of samples 180 remain unassigned. The first possibility is that, despite having mutational patterns compatible 181 with one of the modules, the unassigned samples do not reach the required threshold of 182 statistical significance. That would be the case if mutations affecting module-specific genes 183 occurred in non-coding regions, involved copy number variants, or else, if mutations occurred 184 in functionally equivalent genes not included in our list of cancer-associated genes. The second 185 possibility is that unassigned samples account for exchangeability of cancer-associated genes. 186
Under such a scenario, some cancer types might not be specifically associated to any set of 187
genes. 188
To evaluate the first possibility, we built a set of "best-match extended" modules by attaching 189 unassigned samples and genes to the module with which they shared most connections 190 ( Supplementary Table S2 ). We would expect that, if the specific association between tumors 191 and genes held for most samples within a cancer type, the extended modules would recover 192 unassigned samples from the same cancer types as those already assigned to the original 193 modules. Indeed, the best-match extended modules cluster >75% of the samples from rectum, 194 pancreas, kidney (clear cell), acute myeloid leukemia, thyroid and melanoma, and 50-75% of 195 the samples from lower grade glioma, mesothelioma, colon and endometrial cancer in a 10 tissue-specific way (Fig. 3A) . In contrast, cancer types that were absent from the original 197 modules appear distributed among multiple extended modules, with typically <25% of the 198 samples assigned to the same module (Fig. 3B ). The only exception is ovarian cancer, which 199 does not appear in any of the significant modules although 70% of the samples are recovered 200 as members of the same extended module as lower grade glioma. The apparent cause is the 201 tight association between ovarian cancer and TP53, which is mutated in almost 90% of 202 samples, against a low background of somatic mutations 36 . 203
We confirmed the existence of a diffuse (non-specific) mode of driver accumulation by running 204 the module detection pipeline without removal of non-significant members. The resulting set 205 of "statistically relaxed" modules consists of 12 modules with a counterpart among the original 206 (statistically significant) modules, 16 minor modules with a single gene each and small sample 207 sizes, and a giant, non-significant module that includes 20% of the samples and 90 (45%) genes 208
( Supplementary Table S3 ). The appearance of non-significant (pseudo-)modules is a well-209 known artifact that results from applying module detection algorithms to large networks with 210 partial or no modular structure 37, 38 . In the context of cancers and the associated genes, the 211 giant pseudo-module accounts for the non-modular (diffuse) component of the cancer 212 mutation network, which comprises exchangeable cancer genes that are not specifically 213 associated to particular groups of tumors. Cancer types differ with respect to their 214 contribution to this component. Thus, only 10-20% of samples from cancer types that are 215 represented in the original modules are assigned to the diffuse component, whereas the 216 fraction rises to more than 25% in other cancers (p < 0.01, Wilcoxon test; Fig. 3A and B) . 217
Taken together, these findings indicate that cancer types can be conceptually split into two 218 major groups: (i) those that accumulate driver mutations in specific sets of cancer genes and 219 are accordingly clustered into distinct modules (Table 1) , and (ii) those that accumulate 220 exchangeable driver mutations in a non-tissue-specific manner, such as stomach and lung 221 cancers. Although most cancer types can be clearly placed in one of those two extreme 222 categories, there are some mixed cases ( Fig. 3C ). For example, bladder cancer generates its 223 own module that includes genes KDM6A, FGFR3 and STAG2. However, only 10% of bladder 224 tumors are assigned to that module (30% in the best-match extension), whereas about 40% 225 belong to the diffuse component. Similar, albeit less extreme, trends are observed for head 226 and neck and testicular cancers. Such a mixed mutational landscape, modular for some subsets 227 of the samples, but non-specific for others, seems to mirror the heterogeneity of these cancer 228 types. 229
Copy number alterations 230
We further explored the specificity of driver events by jointly considering somatic mutations 231 and copy number alterations that affect cancer-associated genes. To reduce the number of 232 non-informative connections, only amplifications of oncogenes and losses of tumor suppressor 233 genes were added to the network of somatic mutations. The addition of copy number 234 alterations does not significantly change the results described so far ( Supplementary Tables S4  235   and S5 ). The same significant modules are recovered, although their composition in terms of 236 cancer types is slightly less clean. Besides the modules described above, the addition of the 237 copy number alterations resulted in 5 new modules, none of which showed an obvious 238 correspondence with a particular cancer type. Four of these modules are associated with arm-239 level alterations affecting chromosome arms 7q (genes BRAF, EZH2, MET, and SMO), 9q (genes 240 ABL1, GNAQ, and KLF4), and 17p (genes MAP2K4 and NCOR1), and X chromosome region Xp11 241 (genes BCOR, GATA1, KDM5C, and KDM6A). The fifth of these new modules accounts for 242 frequent loss of 56 cancer-associated genes (mostly tumor suppressors) distributed across the 243 genome. Overall, the inclusion of oncogene amplifications and TSG losses does not reveal the 244 existence of specific modules that were not already detected by the analysis of somatic 245 mutations, although this outcome could be biased by the fact that most cancer-associated 246 genes in our study were identified through mutations. The minor changes in the network 247 structure caused by the inclusion of copy number alterations seem related to the 248 chromosomal location of cancer genes and the opposite trends towards amplification and 249 deletion in oncogenes and TSG, respectively. 250
Average number of driver mutations 251
Identification of driver mutations is confounded by the numerous passenger mutations that 252 are typically found in cancer genomes. Passenger mutations in the coding regions appear to 253 dominate even in cancer-associated genes 9, 39 , resulting in a strong correlation between the 254 number of mutations in cancer-associated and other genes (R = 0.87, p < 10 -20 , Supplementary 255 to the pervasive abundance of passenger mutations, a major feature of the model is the strong 260 correlation between mutations in cancer-associated and non-cancer-associated genes. In this 261 context, the intercepts (which depend on the cancer type) can be interpreted as the excess of 262 mutations in cancer-associated genes that is not attributable to the same causes that lead to 263 the accumulation of mutations in non-cancer-associated genes. Thus, these intercepts 264 constitute a proxy for the number of driver mutations in cancer-associated genes. 265
We found that 75% of the variance in the number of mutations in cancer-associated genes is 266 explained by the number of mutations in passenger genes (ANCOVA, p < 10 -20 ), which is 267 indicative of a common trend of mutation accumulation in both gene classes (Fig. 4A) . 268
Considering all tumors together and controlling for the non-uniform abundances of different 269 cancer types, the mean number of driver mutations per tumor was estimated as 1.82 ± 0.07 270 (95% confidence interval). Differences in the intercepts across tumor classes are statistically 271 significant but explain only 4% of the total variability in the data ( Fig. 4A and B , Supplementary 272 Table S6 ). Such low explanatory power could be due to the heterogeneity of the samples 273 within the same cancer type and possible occurrence of driver mutations in non-coding regions 274 or in genes that do not belong to our list of 198 cancer-associated genes; indeed, 12% of the 275 samples lack coding mutations in these genes. Both limitations can be mitigated by analyzing 276 only samples from significant modules, which represent more homogeneous subsets of tumors 277 enriched in putative driver mutations. Thus, to assess how the number of driver mutations 278 varies across tumors, we repeated the regression analysis with the samples that were assigned 279 to significant modules, using both the assignment to the modules and the cancer type as the 280 grouping variables (Fig. 4A , Supplementary Table S7 ). In samples from significant modules, 281 differences in the number of drivers across cancer types explain 20% of the observed variance 282 in the number of mutations in cancer-associated genes. The predicted number of driver 283 mutations in these samples ranges from values near 1 in glioblastoma, thyroid carcinoma and 284 the subset of melanoma with low mutational load, to values around 5 in bladder, endometrial 285 and head and neck cancers (Fig. 4C) . The average number of drivers per tumor in colorectal 286 cancer is 3.66 ± 0.27, consistent with previous estimates based on epidemiological models 18, 40 287 and measures of positive selection in cancer-associated genes 9 . Notably, the estimates of the 288 average number of driver mutations in the two groups of melanomas differ by almost 2 289
(2.55±0.58 vs 0.68±0.39, respectively), which could be related to the higher mutation burden 290 observed in the first group. 291
Overall, both the number of drivers and the fraction of mutations that are inferred to be 292 drivers tend to be larger in samples from the significant, specific modules. Moreover, the 293 estimated number of driver mutations in these samples closely matches the average number 294 of module-specific (i.e. intra-module) mutations per tumor (Fig. 4D , Spearman's rho = 0.772, p 295 < 0.001). These two findings indicate that modules are held together by genes that carry actual 296 driver mutations in the cancer types that belong to the respective modules. Deviations from 297 the 1:1 trend in Fig. 4D reveal three exceptional cases of limited correspondence between the 298 number of module-specific mutations and the number of estimated drivers. First, the average below the estimated number of drivers, suggesting the existence of driver mutations in genes 301 that do not belong to the module. Second, the number of module-specific mutations in the 302 high-mutation melanoma module is larger than the number of drivers, suggesting that some of 303 the mutations in genes from this module are passengers. 304
There is a strong positive correlation between the estimated number of drivers in a cancer 305 type and the average age at which the respective cancers are diagnosed (Fig. 4E ). This result 306 holds regardless of whether the number of drivers is estimated for the complete set of 307 samples of the given cancer type (Spearman's rho = 0.527, p = 0.003) or for the samples 308 assigned to significant modules only (rho = 0.693, p = 0.005). After controlling for the 309 differences in the number of drivers, cancer types that are and are not associated with 310 significant modules (i.e. with and without specific sets of cancer-associated genes) significantly 311 differ in the average diagnosis age, the former appearing earlier in life (ANCOVA on rank-312 transformed data, p = 0.036, difference = 6.7 rank units). 313 314
Discussion 315
It is a well-established fact that tumors accumulate recurrent mutations in some genes more 316 often than in others. This phenomenon underlies the discovery of oncogenes and tumor 317 suppressor genes and has led to the identification of central pathways for tumorigenesis and 318 tumor progression 7, 8, 10, 12, 41 . Here we went a step further and tested to what extent the 319 association between genes and cancer types is mutually specific and suffices to define 320 coherent, biologically meaningful groups of tumors. Although related to previous research on 321 detection of significantly mutated genes and tumor classification 26, 42, 43 , our approach differed 322 in three major aspects. First, tumor samples were not classified a priori based on their 323 histology, which enabled us to test if different cancer types are distinguishable through 324 comparison of their mutational landscapes alone. Second, genes and samples are jointly could discriminate between cancer types that do and do not show a significant degree of 328 specificity in their sets of mutated genes. 329
Previous studies involving 12 major cancer types have shown that tissue-specific clusters can 330 be automatically identified from genomic and transcriptomic features, suggesting the 331 existence of a consistent molecular basis for a tissue-based classification of tumors 26 . Our 332 analysis provides a generalization of that result to a more diverse dataset that included 30 333 cancer types and 198 cancer-associated genes, revealing major differences among cancer 334 types. Thus, colorectal, pancreatic, endometrial, kidney (clear cell), breast, thyroid, and brain 335 cancers, acute myeloid leukemia, sarcoma, mesothelioma, melanoma and uterine 336 carcinosarcoma are significantly associated with mutations in tissue-specific sets of genes. In 337 contrast, stomach, esophagus and lung cancers, among others, follow a more diffuse, less 338 specific mode of driver accumulation. Some cancers, such as bladder, prostate, testicular 339 (germ cell), and head-and-neck squamous cancer, show a mixed picture, with a significant 340 specificity of mutations observed only in a fraction of samples. 341
The observed specificity patterns of cancer-associated genes could originate from at least two, 342 not mutually exclusive, causes. Biases in mutation and/or repair could make some tissues 343 more prone to accumulating mutations in certain genes (e.g. due to differences in 344 transcription levels, chromatin configuration and exposure to mutational processes) although 345 such biases are unlikely to account for the large differences observed across cancer types 44 . A 346 more important factor is the tissue-specificity of the pathways that control cell proliferation, 347 which have to be overcome for tumor progression through mutations in different genes 45 . This Additionally, it could be hard to find specificity patterns in cancers with high mutational load, 359 such as lung and stomach cancer, due to their low signal (drivers) to noise (passengers) ratio. 360
Nonetheless, the detection of significant modules for bladder cancer and melanoma, which 361 both have high mutational loads 3, 49 , implies that a high mutation burden does not critically 362 affect the performance of the module detection algorithm. Finally, relevant specificity modules 363 based on copy number variation or gene rearrangements could remain undetected if these 364 large-scale mutations involve genes that are not considered here. It should be noted that the 365 absence of specific sets of driver genes for some cancer types does not imply that such cancers 366 cannot be clustered on the basis of other molecular features, as it has been shown for lung 367 adenocarcinoma and lung squamous carcinoma based on transcriptomics 26 . 368
The second major theme of this study is the estimation of the number of driver mutations 369 affecting cancer-associated genes in different cancer types. By comparing the number of 370 mutations in cancer-associated and other genes, we inferred an average of approximately 2 371 driver mutations in cancer genes per tumor, with significant variation (from <1 to >5) across 372 cancer types. Our results generally agree with previously reported numbers based of 373 mutations under positive selection, providing an independent support for such values 9 . 374
Remarkably, there is a connection between driver mutations and tissue-specific, cancer-375 associated genes. Specifically, the number of driver mutations in different cancer types shows the mean age of cancer onset, as one would expect if the number of driver mutations was 380
proportional (yet not necessarily equal) to the number of rate-limiting steps in tumorigenesis 19, 381 21 . Supporting this view, many of the tissue-specific, cancer-associated genes detected in this 382 study are targets of mutations that appear as early clonal events in the trunk of single-tumor 383 evolutionary trees and likely reflect crucial steps in tumor progression 50 . That is, for example, 384 the case of VHL and PBRM1 in clear-cell renal cell carcinoma (often accompanied by parallel 385 subclonal mutations in SETD2) 51 ; DNMT3A and NPM1 in acute myeloid leukemia (often with 386 parallel subclonal mutations in FLT3) 52 ; KRAS, TP53 and SMAD4 in pancreatic cancer 53 ; and 387 APC, KRAS and TP53 in colorectal cancer 54 . 388
We also found an intriguing link between cancer onset and the specificity of cancer-associated 389 genes: cancer types that carry mutations in specific genes tend to appear earlier in life than 390 expected given their estimated number of driver mutations. We suspect that this difference 391 could be explained by the requirement for additional driver mutations in genes that are 392 currently not classified as cancer-associated in the case of the non-specific cancer types and/or 393 by stronger effects of driver mutations in the modular group of cancers. 394 395 396
The results of this work show that rigorous statistical methods for community detection in 397 bipartite networks can shed light on the relationships between different types of tumors and 398 cancer-associated genes. The modularity of the gene-cancer network analyzed here is 399 relatively low, with only about one in four tumor samples included in significant modules. This 400 fraction is likely to increase as more tumors are sequenced and additional cancer-associated 401 genes are identified. Nevertheless, the good agreement between the numbers of driver 402 mutations estimated here and those obtained by other methods, as well as the significant 403 difference in the cancer onset age between the modules and the diffuse component of the 404 network, suggest that the difference between the two modes of carcinogenesis revealed by 405 this analysis withstands the test of time. This distinction between tumors caused by driver 406 mutations in limited sets of tissue-specific genes and those caused by mutations in 407 interchangeable genes that are only weakly linked to specific tumor types could have 408 important implications for understanding cancer evolution as well as diagnostic and 409 therapeutic approaches. Welch's T-test. In the second step, the 200 alternative partitions of the cancer mutation 442 network were used to build a consensus matrix by assigning to each pair of nodes a value 443 equal to the fraction of replicas in which both nodes were assigned to the same module. A 444 distance matrix was then defined as one minus the consensus matrix, and the consensus 445 partition was finally obtained by performing hierarchical clustering on the distance matrix 446 (UPGMA method, implemented by the 'linkage' function in MATLAB version R2015a). The 447 number of clusters was chosen to maximize the Barber's modularity index of the consensus 448 partition with respect to the original network. We refer to the clusters in this consensus 449 partition as the "unfiltered modules". 450
To evaluate the significance of each module separately and filter out the genes and samples 451 that do not follow a modular pattern, we ran the software OSLOM on the original network 452 with the options -singlet -r 0 -hr 0 -t 0.05 -hint, using the unfiltered modules as the reference 453 partition 38 . The significance threshold was set to 0.05. With these settings, OSLOM evaluates patterns observed in the reference partition and removes those nodes that do not reach the 456 required significance threshold. The result is a filtered partition that only includes nodes 457 (genes and samples) with a statistically significant modular structure. As an additional output, 458 OSLOM returns an "extended" partition in which the nodes that do not reach the significance 459 threshold are reassigned to the module that minimizes their p-value. We refer to the modules 460 in such partition as the "extended modules". 461
To test whether the results were robust to the choice of the network partitioning method, we 462 repeated the network analysis using Infomap as the module detection software 59 , both in the 463 first and second steps of the consensus clustering pipeline (in this case, all entries with values 464 >0.4 in the consensus matrix were set to 0, and Infomap was run on the network defined by 465 the consensus matrix constructed with this threshold). Both the unipartite and bipartite 466 versions of Infomap (options set to find hard partitions with 2 levels of hierarchy) were run, 467 followed by the assessment of module significance with OSLOM. In all cases, the results were 468 similar to those presented here ( Supplementary Table S8 ). 469
Estimation of the number of driver mutations 470
To estimate the number of driver mutations in different cancer types, we considered all small 471 coding mutations affecting cancer-associated and non-cancer-associated genes. The function 472 'aoctool' in MATLAB R2015a was used to fit the number of mutations in cancer genes to a 473 "parallel lines" linear model with cancer type and number of mutations in non-cancer-474 associated genes as independent variables. The statistical significance of the model 475 parameters was evaluated with an ANCOVA, with cancer types as factors and the number of 476 mutations in non-cancer-associated genes as covariable. The entire analysis was carried out 477 twice. First, all the samples in the dataset, classified into cancer types, were analyzed. Then, 478 the analysis was limited to the samples that were represented in any of the significant 479 modules. Under the second approach, cancer types represented by fewer than 20 samples 480 were excluded, and cancer types assigned to more than one significant module were split to 481 obtain module-specific estimates. 482
The association between the number of drivers and the age of diagnosis was initially evaluated 483 through a Spearman's correlation analysis. To further assess whether cancer types associated 484 or not to significant modules differ in their age of diagnosis while controlling for the number of 485 driver mutations, an ANCOVA was performed on the rank-converted data, with the number of 486 drivers as a covariable and the inclusion into a significant module as a binary factor. 487 
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